乌鸦传媒

<乌鸦传媒 class="page-title">Meeting Coverage

SABCS Future Focus

<乌鸦传媒 class="page-description">Future Focus from the San Antonio Breast Cancer Symposium
Questions Remain on ADC Sequencing in Metastatic Breast Cancer

Yuan Yuan, MD, discusses the need for evidence-based answers in 2024

image
<乌鸦传媒 class="section_title">Latest SABCS Future Focus Meeting Coverage
PD-L1 Subgroup Benefits Most From Neoadjuvant Immunotherapy in Early Breast Cancer

Lajos Pusztai reviews the two "potentially paradigm-shifting trials"

January 9, 2024
Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer

But sequencing of ADCs such as datopotamab deruxtecan remains an unanswered question

December 29, 2023
SABCS 2023 Highlights Open the Door for More Key Data in 2024

Virginia Kaklamani, MD, discusses this year's sessions of interest and looks ahead to next year

December 22, 2023
Which Studies Will be Practice Changing in Metastatic Breast Cancer?

Jason Mouabbi, MD discusses the most exciting news out of SABCS 2022

December 29, 2022
Does Patient Telehealth Use Affect Breast Cancer Trial Enrollment?

Trial participation not significantly different for patients opting for telemedicine

December 22, 2022
What the SABCS 'Year in Review' Session May Bring in 2023

Virginia Kaklamani, MD, makes some hopeful predictions

December 15, 2022
Emerging Therapies in Metastatic Breast Cancer

Sylvia Adams, MD, shares her view on the future of treatment

December 8, 2022
<乌鸦传媒 class="section_title"> Latest Oncology/Hematology Meeting Coverage